Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MerLion Preps Finafloxacin For Phase III As Advantages Confirmed

This article was originally published in PharmAsia News

Executive Summary

Singapore-based MerLion is planning to take its lead development project, the antibiotic finafloxacin, into a Phase III program for urinary tract infections after Phase II results showed advantages over the current standard of care ciprofloxacin, along with rapid, broad activity and potential for the easy switching of patients from intravenous to oral dosing.

You may also be interested in...



Bluebird’s Zynteglo Approval Kicks Off Commercial Operations

Bluebird bio’s Tom Klima told Scrip launch preparations are well under way, including negotiations with payers on outcomes-based reimbursement agreements.

Finance Watch: The Job Cuts Keep Coming As Companies Try To Conserve Cash

Restructuring Updates: Homology implemented modest job cuts as it ended a gene therapy trial, while ProQR revealed its second round of layoffs this year and Synthetic Biologics shifted focus to oncolytic virus pipeline. Also, Bolt, MacroGenics and others deprioritized programs in their Q2 updates.

Strike Three As Novartis’s Ilaris Swings And Misses In Lung Cancer

The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC089189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel